BioNTech, Duality score initial trial win with breast cancer precision drug

Duality Biotherapeutics

05/09/2025 10:10

FRANKFURT Sept 5 (Reuters) - BioNTech 22UAy.DE and its partner Duality Biologics 9606.HK said on Friday that a late-stage trial testing their precision drug against a certain type of breast cancer reached its main goal of slowing down disease progression.

For COVID-19 vaccine maker BioNTech, the news marks the first success in a cancer trial that could potentially lead to market approval amid a renewed focus on its traditional roots in oncology.

In a joint statement, the partners said that a Phase 3 trial testing experimental drug BNT323 in China in comparison with Roche's ROG.S Kadcyla in certain cases of breast cancer met the primary endpoint of progression-free survival at a pre-specified interim analysis.

 (Reporting by Ludwig Burger, editing by Rachel More)

 ((ludwig.burger@thomsonreuters.com;))